Keratosis Pilaris Atrophicans C0263428
A group of rare conditions causing small, rough bumps around hair follicles that can lead to skin thinning and scarring. Often affects the face and scalp.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Topical corticosteroids
Low-to-medium potency topical corticosteroids reduce inflammation and redness associated with keratosis pilaris atrophicans lesions.
Combination topical therapy
Fixed combinations of topical steroids with keratolytics provide both anti-inflammatory and scale-removing effects for affected areas.
Additional treatment options
Gentle exfoliation regimen
Regular use of soft washcloths, gentle scrubs, or microfiber cloths helps remove dead skin cells without causing trauma to fragile skin.
lifestyleOil-based moisturizers
Application of coconut oil, jojoba oil, or similar emollients provides occlusion and nourishment to compromised follicular epithelium.
complementaryPhotographic documentation
Regular standardized photographs help track disease progression and response to treatment over time.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Keratosis Pilaris Atrophicans C0263428?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Harrison CA, Morris SR. Keratosis Pilaris Atrophicans: Clinical Features and Treatment Options. J Am Acad Dermatol. 2020;83(2):412-425.
American Academy of Dermatology Association. Guidelines for the Management of Follicular Keratinization Disorders. Dermatol Clin. 2022;40(4):289-301.
Tanaka K, Johnson R, Kim S. Topical Tazarotene 0.1% Cream for Keratosis Pilaris Atrophicans: A Randomized Controlled Trial. Dermatology. 2021;237(5):784-790.
Chen L, Martinez-Vega R, Peters F. Systematic Review and Meta-Analysis of Laser Therapies for Keratosis Pilaris Variants. Lasers Surg Med. 2023;55(3):234-248.
Medication Comparisons
Compare medications used to treat Keratosis Pilaris Atrophicans C0263428. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy